

## **Apposite Capital Acquires French Applied Microbiology Company i2a Diagnostics**

**London, UK and Montpellier, France – 2<sup>nd</sup> August 2021.** Apposite Capital, the healthcare investor, today announces that it has completed the Management Buy-in of i2a Diagnostics (“i2a”).

Created in 1988, i2a is a leading provider of instruments, software and reagents for the clinical microbiology market in France. The Company specialises in offering automated solutions across the value chain of the bacteriology clinical testing market, including Antibiotic Sensitivity Testing which identifies bacterial resistance to antibiotics.

As part of the MBI transaction, Arnaud Serfass and Nick Adams will be appointed CEO and non-Executive Chairman of the company, respectively, alongside two of the founders, Jean-Philippe Duvergé and Dominique Curel, who will remain in key roles and on the Board. Michel Emelianoff, Deputy CEO of Visiomed, will also remain on the Board. Apposite and Arnaud Serfass worked closely together for over a year to develop ambitious growth plans for the company.

Arnaud Serfass is a seasoned healthcare professional with a solid track record in expanding businesses internationally. Nick Adams brings 33 years of entrepreneurial and deal making experience in Healthcare. He was the CEO of Bioquell PLC for 18 years which was subsequently sold to Ecolab Inc.

Anne-Laure Meynier, Investment Director at Apposite Capital, who will join the Board of i2a said: “i2a investment is another great example of Apposite Capital’s ability to source proprietary opportunities by partnering with experienced management teams to provide both funding and transaction support to acquire a company. With 700,000 deaths worldwide annually, antimicrobial resistance is a global health priority and Apposite believes that more solutions will be needed to fight it; i2a sees significant opportunities in supporting labs and clinicians with best-in-class solutions to adjust therapy and transform data into actionable insights and we are delighted to be working with Arnaud and the Founding team on this exciting new investment.”

Arnaud Serfass, CEO of i2a, added: “I am delighted to be embarking on this new venture with Apposite Capital. i2a has a truly differentiated and integrated offering combining Antimicrobial Susceptibility Testing solutions with software, and I look forward to continue the expansion of the business internationally.”

Advisers to Apposite Capital: CRSB (legal and tax), Advance Capital (FDD), Constellation Law (IP)  
Advisers to i2a: K&L Gates (legal), Société Générale (financial advisory to minority sellers)

-end-

**Media contact:**

Anne-Laure Meynier

Tel : +44(0)203 475 1710

Email: [anne-laure.meynier@appositecapital.com](mailto:anne-laure.meynier@appositecapital.com)

**About Apposite Capital** ([www.appositecapital.com](http://www.appositecapital.com))

Apposite Capital is an independent investment firm focused exclusively on healthcare. It backs companies operating in health and social care, medtech & medical products, pharmaceuticals & life sciences and digital health.

Apposite Capital operates at the small end of the private equity market, providing both capital and expertise to those businesses offering 'disruptive' models that aim to improve or reduce the cost of care provision and which have the potential to become market leaders.

Apposite has an in-depth sector knowledge covering key aspects of the healthcare industry internationally, an exceptional network and an entrepreneurial mindset which it applies to drive the growth of its portfolio companies.

Apposite Capital was established in 2006 and is headquartered in London, UK.

**About i2a** ([www.i2a-diagnostics.fr](http://www.i2a-diagnostics.fr))

Created in 1988, i2a is a leading provider of laboratory instruments, software and reagents for the clinical microbiology market in France and provides hospitals with integrated solutions for antibiotic susceptibility testing in order to support timely and accurate antibiotic therapy and therefore help combat antimicrobial resistance.